Impact of chemotherapy-induced nausea and vomiting on quality of life in Indonesian patients with gynecologic cancer

International Journal of Gynecological Cancer

Volumn 22, Issue 1, 2012, Pages 139-145

  Perwitasari, Dyah Aryani ^a,b,c   Atthobari, Jarir ^b   Mustofa, Mustofa ^b   Dwiprahasto, Iwan ^b   Hakimi, Mohammad ^b   Gelderblom, Hans ^c   Putter, Hein ^c   Nortier, Johan W R ^c   Guchelaar, Henk Jan ^c   Kaptein, Ad A ^c  

^a UNIVERSITAS AHMAD DAHLAN   (Indonesia)

^b GADJAH MADA UNIVERSITY   (Indonesia)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Chemotherapy; EORTC QLQ C30; Gynecologic cancer; Indonesia; Nausea and vomiting; SF 36

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; FLUOROURACIL; METOCLOPRAMIDE; ONDANSETRON;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; DRUG INDUCED DISEASE; DRUG MEGADOSE; EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT FOR CANCER OF QUALITY OF LIFE QUESTIONNAIRE; FEMALE; GYNECOLOGIC CANCER; HUMAN; INDONESIA; MAJOR CLINICAL STUDY; NAUSEA AND VOMITING; OUTCOME ASSESSMENT; OVARY CANCER; PRIORITY JOURNAL; QUALITY OF LIFE; QUALITY OF LIFE INDEX; QUESTIONNAIRE; SHORT FORM 36; UTERINE CERVIX CANCER; UTERUS CANCER; VULVA CANCER;

ADULT; AGED; ANTIEMETICS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; INDONESIA; MIDDLE AGED; NAUSEA; QUALITY OF LIFE; QUESTIONNAIRES; VOMITING;

EID: 84858271243     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e318234f9ee     Document Type: Article

References (23)

1. Cohen L, deMoor CA, Eisenberg P, et al. Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings. Support Care Cancer. 2007;15:497-503. (Pubitemid 46570778)
2. Navari RM. Antiemetic control: toward a new standard of care for emetogenic chemotherapy. Expert Opin Pharmacother. 2009;10:629-644.
3. Trigg ME, Higa GM. Chemotherapy-induced nausea and vomiting: antiemetic trials that impacted clinical practice. J Oncol Pharm Pract. 2010;16:233-244.
4. Perwitasari DA, Gelderblom H, Atthobari J, et al. Anti-emetic drugs in oncology: pharmacology and individualization by pharmacogenetics. Int J Clin Pharm. 2011;33:33-43.
5. Majem M, Moreno ME, Calvo N, et al. Perception of healthcare providers versus patient reported incidence of chemotherapy-induced nausea and vomiting after the addition of NK-1 receptor antagonists [published online ahead of print November 18, 2010]. Support Care Cancer.
6. Melville A, Eastwood A, Kleijnen J, et al. Management of gynaecological cancers. Qual Health Care. 1999;8:270-279.
7. Kris MG, Hesketh PJ, Somerfield MR, et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol. 2006;24:2932-2947. (Pubitemid 46630595)
8. Penson RT, Wenzel LB, Vergote I, et al. Quality of life considerations in gynecologic cancer. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006;95:S247-S257.
9. Available at: http://globocan.iarc.fr/. Accessed October 3, 2010.
10. Perwitasari DA, Atthobari J, Dwiprahasto I, et al. Translation and validation of EORTC QLQ-C30 into Indonesian version for cancer patients in Indonesia. Jpn J Clin Oncol. 2011;41:519-529.
11. Koller M, Aaronson NK, Blazeby J, et al. Translation procedures for standardised quality of life questionnaires: the European Organisation for Research and Treatment of Cancer (EORTC) approach. Eur J Cancer. 2007;43:1810-1820. (Pubitemid 47238253)
12. van de Poll-Franse LV, Mols F, Gundy CM, et al. Normative data for the EORTC QLQ-C30 and EORTC-sexuality items in the general Dutch population. Eur J Cancer. 2011;47:667-675.
13. Ware JE Jr, Gandek B. Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project. J Clin Epidemiol. 1998;51:903-912. (Pubitemid 28527145)
14. Apolone G, Filiberti A, Cifani S, et al. Evaluation of the EORTC QLQ-C30 questionnaire: a comparison with SF-36 Health Survey in a cohort of Italian long-survival cancer patients. Ann Oncol. 1998;9:549-557. (Pubitemid 28270644)
15. van der Zee KI, Sanderman R. Rand-36 . Manual. Groningen, The Netherlands: Noordelijk Centrum voor Gezondheidsvraagstukken; 1993.
16. Double-blind, dose-finding study of four intravenous doses of dexamethasone in the prevention of cisplatin-induced acute emesis. Italian Group for Antiemetic Research. J Clin Oncol. 1998;16:2937-2942.
17. Hilarius DL, Kloeg PH, van der Wall E, et al. Chemotherapy-induced nausea and vomiting in daily clinical practice: a community hospital-based study [published online ahead of print January 22, 2011]. Support Care Cancer. doi: 10.1007/s00520-010-1073-9.
18. Bhatia A, Tripathi KD, Sharma M. Efficacy & tolerability of ondansetron compared to metoclopramide in dose dependent cisplatin-induced delayed emesis. Indian J Med Res. 2004;120:183-193. (Pubitemid 39406046)
19. Boini S, Briancon S, Guillemin F, et al. Impact of cancer occurrence on health-related quality of life: a longitudinal pre-post assessment. Health Qual Life Outcomes. 2004;2:4.
20. Noonan K. The impact of chemotherapy induced nausea vomiting on the daily function and quality of life of patients. Adv Stud Nurs. 2005;3:16-21.
21. Biegler KA, Chaoul MA, Cohen L. Cancer, cognitive impairment, and meditation. Acta Oncol. 2009;48:18-26.
22. Lachaine J, Yelle L, Kaizer L, et al. Chemotherapy-induced emesis: quality of life and economic impact in the context of current practice in Canada. Support Cancer Ther. 2005;2:181-187.
23. Grunberg SM, Deuson RR, Mavros P, et al. Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer. 2004;100:2261-2268. (Pubitemid 38580348)